Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ICUI vs THOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICUI Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

ICUI Overall Winner 6-Pillar Tally: ICUI 5 – 0 THOR (1 Tie) Matrix Metrics: ICUI 9 – 1 THOR

As of Nov 20, 2026, ICU Medical Inc (ICUI) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ICUI carries a Unified Composite Score of 49.5/100 (HOLD) at $172.52 (17.8x Forward P/E, 6.7% operating margin), whereas THOR carries 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ICUI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.9); meanwhile THOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ICUI vs THOR
ICUI NASDAQ Head-to-Head Winner
ICU Medical Inc
Surgical & Medical Instruments & Apparatus
$172.52
-1.84% 1D
Market Cap $4.4B
TTM Revenue $2.18B
Forward P/E 17.8x
Beta / 30D Vol 0.86β · 38% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 45.0 Fund 47.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $172.29 · SMA50: $165.37
THOR US Equity
THOR
Institutional Equity
$24.63
-1.7% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 17% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 27.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 32
RSI-14: 31.7 · SMA20: $25.77 · SMA50: $25.60

6-Pillar Scorecard Institutional Category Breakdown (ICUI 5 – 0 THOR)

Columns: Metric · ICUI · THOR
1. Valuation Multiples ICUI
Forward P/E 17.8x N/M
Trailing P/E 73.5x N/M
PEG Ratio 0.09x N/M
EV / Revenue 2.0x N/M
2. Growth & Scale ICUI
Revenue Growth (YoY) +4.4% N/A
Earnings Growth (YoY) -46.9% N/A
TTM Revenue (USD) $2.18B N/A
Market Cap $4.4B N/A
3. Profitability & Quality ICUI
Gross Margin 38.9% N/A
Operating Margin 6.7% N/A
Net Profit Margin 2.8% N/A
Return on Equity (ROE) 2.8% N/A
4. Balance Sheet & Cash Flow ICUI
Cash Generation (TTM) $346M EBITDA N/A
Cash Flow Margin 15.9% EBITDA Mgn N/A
Net Cash / Leverage $87.62 Book/Sh · 2.8% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 39.9% (2nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ICUI
OpEx & R&D Intensity 32.2% of Rev ($703M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ICUI (9) vs THOR (1)
Institutional Metric ICUI THOR Criterion Row Edge
Market Capitalization
Scale
$4.4B N/A Larger Scale ICUI
Trailing P/E Ratio
Valuation
73.5x N/M Lower Multiple ICUI
Forward P/E Ratio
Valuation
17.8x N/M Lower Multiple ICUI
Revenue Growth (YoY)
Growth
+4.4% N/A Higher Growth ICUI
Operating Margin (TTM)
Profitability
6.7% N/A Higher Margin ICUI
Net Profit Margin
Profitability
2.8% N/A Higher Margin ICUI
Return on Equity (ROE)
Capital Efficiency
2.8% N/A Higher ROE ICUI
52-Week Range Position
Momentum
74% ($113–$193) 2% ($25–$29) Stronger Trend ICUI
Beta / 30D Volatility
Risk Regime
0.86β · 38% Vol 0.46β · 17% Vol Lower Realized Risk THOR
Unified Institutional Score
Composite Signal
49.5 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite ICUI
Trailing 12M Revenue (USD)
Operating Scale
$2.18B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
38.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.09x PEG · 2.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$346M EBITDA ($87.62 Book/Sh · 2.8% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ICUI +6.41 pp
ICUI: +2.49% · THOR: -3.92%
3M Horizon ICUI +1.97 pp
ICUI: -5.49% · THOR: -7.46%
6M Horizon ICUI +28.73 pp
ICUI: +27.3% · THOR: -1.43%
1Y Horizon ICUI +28.73 pp
ICUI: +27.3% · THOR: -1.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICUI vs THOR. Trailing 12-month operating profitability (ICUI 6.7% vs THOR N/A) and valuation multiples (ICUI 17.8x vs THOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ICUI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.18B
Gross Margin38.9%
Op. Margin6.7%
ROE / Fwd P/E2.8% · 17.8x
THOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ICUI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 39.9%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICUI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
THOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact THOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ICUI Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $4.4B market capitalization and 6.7% operating margin.
OpEx & R&D Reinvestment 32.2% of Rev ($703M)
90D Engineering Disclosures 0 Published
THOR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ICUI vs THOR Key Questions & Quantitative Answers

As of Nov 20, 2026, ICU Medical Inc (ICUI) is the stronger overall head-to-head candidate over THOR (THOR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ICUI carries a Unified Composite Score of 49.5/100 (HOLD) at $172.52 (17.8x Forward P/E, 6.7% operating margin), whereas THOR carries 44.5/100 (HOLD) at $24.63 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ICUI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.9); meanwhile THOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ICUI leads the Growth & Scale pillar: ICUI posts +4.4% YoY revenue growth and -46.9% YoY earnings growth on $2.18B TTM revenue (38.9% gross margin, 6.7% operating margin), compared with THOR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ICUI generates $2.18B in USD-normalized revenue versus N/A for THOR. In operating R&D and SG&A reinvestment, ICUI deploys 32.2% of Rev ($703M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for THOR.

ICUI screens cheaper on headline valuation multiples. ICUI trades at 17.8x Forward P/E, 73.5x Trailing P/E, 0.09x PEG, and 2.0x EV/Revenue (15.9% EBITDA margin), whereas THOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICUI (2.8% ROE) versus THOR (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ICUI carries 39.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.86β · 38% Vol realized risk). By comparison, THOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 17% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.